Fast-To-Market Play For AstraZeneca's Acalabrutinib With MCL Filing

Never mind MYSTIC, AstraZeneca is pushing the spotlight onto its other oncology assets, and its second-generation BTK inhibitor has just been accepted for filing and given breakthrough status in the US.